Martin J. Joyce left the role of Director at Aldeyra Therapeutics, Inc. As of November 7, 2026, Aldeyra Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 20, 2026 to June 10, 2026, naming 1 departure (Form 8-K, April 20, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Aldeyra Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Aldeyra Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-20 to 2026-06-10. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Aldeyra Therapeutics, Inc. files it.
Also on the record for Aldeyra Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13G, by Barclays PLC | 5.48% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G, by AQR Capital Management, LLC | 6.22% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1.7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | — | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 7% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 8.7% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 6.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Aldeyra Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Aldeyra Therapeutics, Inc. and the records around it.
Aldeyra Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)
- Barclays PLC also filed stake reports on 116 other companies: BIGLARI HOLDINGS INC-B (Nov 2026), CABLE ONE INC (Nov 2026), CALISA ACQUISITION CORP (Nov 2026)
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
Watch Aldeyra Therapeutics, Inc.
Get an email when Aldeyra Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aldeyra Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Aldeyra Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aldeyra Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-10 | Reported | not named in the filing | 8-K, 2026-06-10 | ||
| 2026-04-20 | Out | Director | 8-K, 2026-04-20 |
Who leads Aldeyra Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Martin J. Joyce, departure reported (filed 2026-04-20). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Aldeyra Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Aldeyra Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Aldeyra Therapeutics, Inc.Every change, in the filing's words
Reported
(d) On June 9, 2026, following Aldeyra Therapeutics, Inc.'s (the "Company") 2026 annual meeting of stockholders (the "2026 Annual Meeting"), and based upon the recommendation of the Nominating/Corporate Governance Committee of the Board of Directors (the "Board"), the Board appointed Darlene Deptula-Hicks as a Class III director, with her initial term expiring at the Company's 2029 annual meeting of stockholders.
- Further, the Board appointed Ms. Deptula-Hicks to serve as Chair of the audit committee of the Board (the "Audit Committee").
- The Company has determined that Ms. Deptula-Hicks is independent under the rules and regulations of the Securities and Exchange Commission ("SEC") and the listing standards of The Nasdaq Stock Market LLC ("Nasdaq") applicable to audit committee members.
- In addition, the Board has determined that Ms. Deptula-Hicks qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirement of Nasdaq.
- Pursuant to the Company's non-employee director compensation program, as a non-employee joining the Board, Ms. Deptula-Hicks was granted a non-statutory stock option to purchase 94,313 shares of the Company's common stock on June 9, 2026 with an exercise price equal to the closing stock price of the Company's common stock on The Nasdaq Capital Market on June 9, 2026.
- This option will vest ratably in annual installments over three years of service following the date of grant.
- Ms. Deptula-Hicks will also receive an annual fee of $40,000 for service as a director, and an annual fee of $7,500 for service as Chair of the Audit Committee.
Departing: Martin J. Joyce, Director
(b) On April 20, 2026, Martin J. Joyce, a member of the Board of Directors of Aldeyra Therapeutics, Inc. ("Aldeyra"), notified Aldeyra of his decision to not stand for re-election at the upcoming 2026 annual meeting of stockholders (the "2026 Annual Meeting").
- Mr. Joyce will continue to serve until his term expires at the 2026 Annual Meeting.
- The decision by Mr. Joyce to not stand for re-election was not the result of any disagreement with Aldeyra.
Tools for this story
Each opens in a new tab, filled in for Aldeyra Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.